«To our knowledge there have been no studies examining the effect of antioxidants in recurrent
wheezing following infant viral ARIs.
Not exact matches
Descriptive statistics and multiple logistic regression analysis relating sleep position at each
follow - up age to symptoms in the prior week (fever, cough,
wheezing, stuffy nose, trouble breathing or sleeping, diarrhea, vomiting, or spitting up) and outpatient visits in the prior month (ear infection, breathing problem, vomiting, spitting up, colic, seizure, accident, or injury).
Main Outcome Measures Descriptive statistics and multiple logistic regression analysis relating sleep position at each
follow - up age to symptoms in the prior week (fever, cough,
wheezing, stuffy nose, trouble breathing or sleeping, diarrhea, vomiting, or spitting up) and outpatient visits in the prior month (ear infection, breathing problem, vomiting, spitting up, colic, seizure, accident, or injury).
In «Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent
Wheezing: 6 Year
Follow - up Study,» researchers report on multicenter case - control study of 444 Japanese infants born at 33 - 35 weeks gestation.
Our study results suggest that this could be an effective
wheezing prevention strategy
following infant viral ARIs, however, research would first need to be done to determine the effects, adequate dosing and safety of certain antioxidant agents in infants before they can be recommended for this use.»
Those with a history of recurrent
wheeze or asthma underwent further
follow - up four weeks later.
The
wheezing that is the distinguishing symptom of this disorder is usually
followed by a dry, hacking cough.
Although his condition did improve slightly, our medical staff noticed a persistent
wheezing and abnormalities on
follow up x-rays.